Cipla Injects Scale With $550m US Buy
This article was originally published in PharmAsia News
Executive Summary
Cipla is acquiring the US-based firms InvaGen Pharmaceuticals and Exelan Pharmaceuticals for $550m, a deal which is expected to arm the India company with a ready basket of on-market generic drugs and attractive filings in addition to a manufacturing base as it ramps up in the US.
You may also be interested in...
Decade In Review: C-Suite Shifts At Family-Owned Indian Firms
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.
Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.